News & Updates
Showing Cardiology articles
Showing
Show Multimedia Only

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
25 Nov 2025
byStephen Padilla
The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.
Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
25 Nov 2025
Limited sugar exposure in early life may prevent CVD events in adulthood
15 Nov 2025
byStephen Padilla
Restricting sugar exposure in utero and during infancy appears protective against the risks of several cardiovascular outcomes and delays disease onset later in life, suggests a study.







